Clinical trials are the central event in the life of a biotech company. They determine whether the science works in patients, whether regulatory approval is achievable, and ultimately whether the company’s pipeline has value. The CEO of a clinical-stage biotech is accountable for trial outcomes in ways that feel deeply personal, because the results of clinical programs determine the company’s future.
This accountability creates a delegation paradox. Clinical trials feel too important to delegate operationally. But the operational complexity of running a clinical trial, with all of its site management, data management, protocol compliance, safety reporting, and regulatory communication demands, is simply too great for the CEO to manage personally while also leading the organization.
Understanding how to resolve this paradox is one of the most important leadership skills a biotech CEO can develop.
What Clinical Trial Oversight Actually Requires of the CEO
The CEO of a clinical-stage biotech is not expected to be the clinical operations manager of their trials. What they are expected to do is:
Ensure the right scientific and operational leadership is in place to execute trials of the required quality. Make the strategic decisions that affect trial design, indication choice, patient population, and regulatory strategy. Monitor trial progress at the level of strategic milestone performance. Engage immediately and appropriately when serious safety events occur, when trials face the risk of failure, or when regulatory relationships require CEO-level engagement. Communicate clinical progress credibly to investors, board members, and partners.
None of these responsibilities requires the CEO to be involved in day-to-day trial operations. All of them require enough clinical understanding to engage meaningfully when the strategic moments arise.
The CMO as the CEO’s Primary Clinical Delegate
The Chief Medical Officer is the most critical clinical delegation relationship a biotech CEO holds. The CMO should be the person who ensures clinical programs are designed with scientific rigor, executed with operational quality, and managed within the strategic parameters the CEO has set.
The CEO-CMO relationship should be built on three foundations: alignment on scientific strategy and trial design rationale, clear communication about the CEO’s decision involvement expectations, and regular structured briefings that keep the CEO informed without requiring CMO time to manage daily CEO requests.
The CEO should expect from the CMO: proactive communication when a trial is encountering difficulty, clear recommendations when strategic decisions are needed, and honest assessment of program risks and probability of success.
The CEO should give to the CMO: genuine decision-making authority within the clinical program scope, organizational backing when clinical leadership decisions are challenged, and access to the CEO for urgent escalations without bureaucratic friction.
Delegating Trial Operations to Clinical Operations Leadership
Below the CMO, a VP of Clinical Operations or Head of Clinical Operations should own the trial execution function. Their responsibilities include: managing the clinical project management team, overseeing CRO relationships, monitoring site performance, ensuring protocol compliance, managing data quality, and maintaining trial timelines and budgets.
The CEO does not attend trial status meetings, review individual site performance metrics, or manage CRO relationships at the operational level. These functions belong entirely to the clinical operations team.
The CEO receives a clinical program dashboard from the CMO: a regular summary of trial status across all active programs, with flagged items requiring CEO attention. This dashboard replaces direct operational involvement.
For the broader pharma and biotech clinical delegation framework, see pharma clinical operations.
CEO Engagement at Key Clinical Decision Points
While operational trial management is delegated, there are specific clinical decision points that require CEO engagement. These include:
Protocol amendments that significantly change the trial design, endpoints, or patient population. These decisions have regulatory, commercial, and scientific implications that extend beyond the CMO’s domain.
Go/no-go decisions for advancing to the next trial phase: the decision to enter Phase 3 is typically the single largest investment decision a clinical-stage biotech CEO makes.
Interim analysis and data review results: when an independent Data Monitoring Committee provides recommendations or when interim analyses produce unexpected results, the CEO needs to understand the implications for program strategy and investor communication.
Clinical hold decisions: if a regulatory agency places a clinical hold on a trial due to a safety signal, the CEO must be immediately engaged for both operational response and external communication.
Pivotal trial design decisions: the endpoint choices, patient population, trial powering, and comparator selection for a pivotal trial directly affect the probability of regulatory approval and commercial positioning.
Safety Event Management and the CEO
Serious adverse events in clinical trials require clear escalation protocols. The CEO must be informed of serious, unexpected drug-related adverse events, particularly those that might affect the trial’s risk-benefit assessment or trigger regulatory reporting requirements.
Build a safety escalation protocol with the CMO and Chief Safety Officer. Define: which categories of events trigger immediate CEO notification, what information the CEO should receive in the initial notification, what the CEO’s response role is, and who manages external communications about safety events.
For most safety events, the CMO and pharmacovigilance team manage the response operationally. The CEO is informed, provides strategic direction for external communications, and engages directly with the most significant events.
Safety culture in a biotech company is set by the CEO’s demonstrated attitude toward patient safety. CEOs who make clear that no commercial consideration will override appropriate response to safety signals create organizations that identify and report safety issues early, which ultimately protects both patients and the company.
Managing Regulatory Interactions During Trials
Regulatory interactions during clinical trials, including end-of-phase meetings, special protocol assessment requests, safety reporting, and protocol amendment submissions, require expertise from the Regulatory Affairs team. The VP of Regulatory Affairs or Chief Regulatory Officer should manage the regulatory function operationally.
The CEO participates in regulatory interactions at the most senior levels: meetings with FDA senior leadership for significant regulatory negotiations, and strategic decisions about regulatory strategy that affect trial design or development timelines.
The regulatory team manages the preparation, submission, and follow-up for all regulatory interactions. They brief the CEO on material regulatory developments and prepare them for significant regulatory meetings.
See pharma regulatory affairs for the detailed framework on how CEO regulatory delegation functions in practice.
Investor Communication During Trials
Clinical trial progress is often the primary driver of biotech investor interest and valuation. Managing investor communication during a trial requires a disciplined approach that balances disclosure obligations with appropriate information control.
An Investor Relations function, typically led by a Head of IR, manages the investor communication infrastructure: monitoring disclosure requirements, preparing the CEO for investor interactions, managing analyst relationships, and coordinating clinical milestone announcements.
The CEO leads the external communication of clinical results: presenting data readouts to investors, participating in earnings calls, and engaging with major institutional investors on clinical strategy. The IR function manages the preparation, logistics, and ongoing investor relationship infrastructure.
When a clinical readout occurs, the CEO must be prepared to communicate results clearly and credibly, whether positive or negative. This requires adequate preparation from the IR and communications team, and it requires a CEO who has maintained enough engagement with the clinical program to communicate authentically.
According to Harvard Business Review, biotech CEOs who maintain genuine scientific engagement with their clinical programs, rather than delegating all scientific understanding along with the operations, build significantly stronger investor and partner confidence than those who rely entirely on their CMO to explain the science.
Managing CRO Partnerships During Trials
Most clinical-stage biotechs rely on CROs to execute significant portions of their trial operations. CRO management requires dedicated attention from the clinical operations team: performance oversight, issue escalation, contract management, and relationship maintenance.
The VP of Clinical Operations owns CRO relationships operationally. The CEO might engage with a CRO relationship at the senior executive level during initial partnership establishment or when significant performance issues require escalation that has not been resolved at the operational level.
For routine CRO management, the CEO should not be involved. CRO performance management is operational work that the clinical operations leadership should own.
Building Trial Readiness Before Delegation Can Work
Effective delegation of clinical trial management requires that the organizational infrastructure for trials is actually in place. Many clinical-stage biotechs attempt to delegate clinical operations before they have built the internal clinical leadership team, the SOPs, the quality systems, and the oversight structures that make delegation safe.
The CEO’s job before delegating is to ensure this infrastructure exists: that the CMO has the experience and credibility to lead the clinical program, that the clinical operations function has the depth to manage trial complexity, that quality systems are in place to maintain data integrity, and that the regulatory function can support the agency interactions the program requires.
Delegating to a clinical infrastructure that is not ready does not reduce CEO responsibility for outcomes. It increases it, because the delegate cannot actually carry the work.
Conclusion
Biotech CEOs lead companies where clinical trial outcomes determine organizational destiny. This makes trial management feel undelegatable. But the clinical operating infrastructure, from site management and data quality to CRO performance and safety reporting, requires specialized expertise and daily attention that the CEO cannot personally provide.
The resolution is clear: build the clinical leadership team, establish the oversight structures, define the escalation protocols, and maintain the CEO engagement at the strategic decision points that genuinely require it. Then step back from the operational management and trust the clinical organization you have built to execute at the quality your patients and your company deserve.
Related Reading
For further context, explore How Biotech CEOs Delegate R&D and Scientific Team Responsibilities and Automotive CEO Delegation for Aftermarket and Parts.